LTX-109

DRUG2 trials

Sponsors

Lytix Biopharma AS

Conditions

Atopic DermatitisGram-positive, Skin InfectionsMild Eczema/DermatosesNasal Carriers MRSA

Phase 1

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)

CompletedNCT01158235

Lytix Biopharma ASNasal Carriers MRSA

Start: 2010-05-31End: 2011-04-30Target: 24Updated: 2011-06-08

Phase 2

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

CompletedNCT01223222

Lytix Biopharma ASAtopic Dermatitis, Gram-positive, Skin Infections, Mild Eczema/Dermatoses

Start: 2010-09-30End: 2011-02-28Target: 24Updated: 2011-02-16

Related Papers

LTX-109 Is a Novel Agent for Nasal Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus

Antimicrobial Agents and Chemotherapy2014-10-2197 citations